GWLL 0.29 Goldenwell Biotech, Inc.
| Range: | 0.0586-0.3275 | Vol Avg: | 343 | Last Div: | 0 | Changes: | -0.03 |
| Beta: | 2.72 | Cap: | 0.02B | Currency: | USD | Exchange: | PNK |
| Sector: | Consumer Defensive | IPO: | Fri Sep 30 2022 | Empoloyees: | |||
| CUSIP: | CIK: | ISIN: | US38138N1046 | Country: | US | ||
| CEO: | Mr. Shuang Liu | Website: | https://www.goldenwellbiotech.com | ||||
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. The company is developing five products, including JI MAIbovine cardiac vascular active peptide; cartilage peptide, a type II collagen peptide; and Double Proline AG 3D active collagen peptide, as well as DNA repair tablets and sugar master tablets. The company was incorporated in 2019 and is based in Twinsburg, Ohio.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow